The Australia-based biotechnology company, which is now part of Novo Ventures' portfolio, has raised $64m in its last two rounds.

Eli Lilly-backed cancer drug developer Cerulean Pharma priced its initial public offering at $7.00, considerably below the range originally set.

The Proteosys-backed pharmaceutical company, formed through a merger last year, is also set to raise $26m from a concurrent private placement to Johnson & Johnson.

The Irish government agency will invest up to $16m in the Mayo-backed venture, which will aim to commercialise US medical technology at Irish universities.

The US-based metabolic disease treatment developer has raised $165m since 2002, but plans to raise only $30m when it goes public.

Life sciences-focused private equity firm BVCF has completed a third fund that will target China-based investments, and Novartis is amongst the backers.

AdvanDx, which develops treatments to combat hospital infections, has secured $12m in its latest round, which included pharmaceutical company Merck.

Omada, a developer of treatments for diabetes, has now received $28.5m in funds from investors including Kaiser Permanente.

The Legend Holdings-backed aortic valve medical device developer has extended its series C by a further $10m after reaching a $62.5m first close last year.

HGTF has received financing from Germany-based pharmaceutical company Bayer, which has become the twentieth investor in its High-Tech Gruenderfonds II fund.